AML ön tanılı olgularda inv(16) CBFBETA- MYH11 inversiyonunun real time RT - PCR ile 5 yıllık sonuçlarının değerlendirilmesi

Amaç: Bu çalışmada, Ege Üniversitesi Tıp Fakültesi Tıbbi Biyoloji Anabilim Dalına 2009-2013 yılları arasında akut myeloid lösemi (AML) ön tanısı ile başvuran 402 olgunun (322 yetişkin, 80 çocuk) kan veya kemik iliği örneklerinin inv16 kantitasyon analizlerinin RT-PCR yöntemi ile değerlendiril mesi amaçlandı. Gereç ve Yöntem: Hastalardan alınan kan ve kemik iliği örneklerinden total RNA/mRNA izolasyonunu takiben cDNAları elde edil erek revers -transkriptaz -polimeraz zincir reaksiyonu (RT-PCR) yöntemiyle inv16 kanti tasyonu LightCycler2 cihazında gerçekleştiril di . Bulgular: Dört yüz iki olgu , inv(16) CBFBETA-MYH11 inversiyonu açısından değerlendiril di . Yapılan analiz sonucunda 12 (% 4) erişkin ve 7 (% 9) çocuk olmak üzere toplam 19 olguda inv16 pozitifliği saptan dı . Sonuç: I nv16 kantitatif analizi, AML hastalarının klinik değerlendirilmesinde, hastalığın seyri ve remisyon sağlanmasına yönelik tedavi protokollerinin uygulanmasında etkili bir yöntem olduğu nu desteklemektedir. AML hasta grubunu içeren daha geniş kapsamlı çalışmalar yapılarak elde edilen sonuçlar desteklenmelidir.

Evaluation of 5 - year results of the inversion of inv(16) CBFBETA- MYH11 with real time RT- PCR in patients prediagnosed as AML

Aim: In this study, it was aimed to evaluate the analysis of inv16 blood and bone marrow samples quantitive ly by reve rse transcriptase polymerase chain reaction (RT-PCR ) method of 402 patients (322 adult, 80 children) prediagnosed as acute myeloid leukemia (AML), who were admitted to Ege University Faculty of Medicine, Department of Medical Biology between years 2009 -201 3. Materials and Methods: cDNAs were obtained following the total RNA/mRNA isolation which were taken from patients blood and bone marrow samples and quantitaion of inv16 were performed by reverse transcriptase RT-PCR method at LightCycler2. Results: Four hundred and two cases were evaluated in terms of inv(16) CBFBETA -MYH11 inversion. As a result of the analysis, a total of 19 patient were determined inv16 positivity includes 12 adult (% 4) and 7 children (9%).Conclusion: Inv16 of quantitative analysis is supported to be an e ffective method for clinical evaluation of patients with AML, regarding remission of disease and implimentation of the treatment protocols toward achieving remission. More studies with AML patients are required for confirmation of the results.

PDF

___

1. Adriaansen HJ, te Boekhorst PA, Hagemeijer AM, van der Schoot CE, Delwel HR, van Dongen JJ. Acute m yeloid l eukemia M4 with b one m arrow e osinophilia (M4Eo) and inv(16)(p13q22) exhibits a s pecific i mmunophenotype with CD2 expression . Blood 1993; 81(11):3043 -51.
2. Elias JJ, Eliheu E, Hagop MK. Adult acute m yeloid l eukemia. Mayo Clin Proc 2006; 81(2): 247 -60 .
3. Bart L, Yue H, Kristie LD, and Scott WH. The inv(16) encodes an acute myeloid leukemia 1transcriptional corepressor. PNAS 1999;96(22):12822 -27.
4. Kristie LD, Bart L, Tanawan K, Alan DF, Scott WH. The inv(16) fusion p rotein associates with corepressors via a s mooth m uscle m yosin h eavy -c hain d omain. Mol Cell Biol 2003;23(2):607 -19.
5. Carlos AT, Federico V, Laura K, et al. Acute myeloid leukemia with inv(16) with CBFBeMYH11, 30 CBFB deletion, variant t(9;22) with BCR -ABL1, and del(7)(q22q32) in a pediatric patient: Case report and literature review. Cancer Genet Cytogenet 2010;200 (1) :54 -9.
6. Kobayashi T, Ichikawa M, Kamiku bo Y, Kurokawa M. Acute myeloid leukemia with cryptic CBFB -MYH11 type D. Int J Clin Exp Pathol 2013;6(1):110 -2.
7. Susanne S, Martin W, Claudia S, Wolfgang H, Torsten H, Wolfgang K. New score predicting for prognosis in PML -RARA, AML1 -ETO, or CBFB- MYH11 acu te myeloid leukemia based on quantiﬁcation of fusion transcripts. Blood 2003;102(8):2746 -55.
8. Yasemin S, Muhterem B, Cengiz Y, Ahmet İ, Emin K. Lösemilerin g enetik tanısında s itogenetik ve floresan i n s itu h ibridizasyon yöntemlerinin e tkinliğinin d eğerlendi rilmesi. Kocatepe Tıp Derg 2009;10 (1):41 -7.
9. Fischer K, Scholl C, Salat J, Dohner H. Design and validation of DNA p robe sets for a c omprehensive i nterphase c ytogenetic analysis acute myeloid leukemia . Blood 1996;88(10):3962 -71.
10. Anastasi J. Genetic and m olec ular g enetic studies in the d iagnosis of myeloid diseases. Hum Pathol 2003;34 (4):306 -13.
11. Marlton P, Keating M, Kantarjian H , et al. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. Leukemia 1995;9(6):965 -71.
12. Liu PP, Hajra A, Wijmenga C, et al. Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia. Blood 1995;85(9):2289 -302.
13. Delaunay J, Vey N, Leblanc T, et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): A s urvey of 110 cases from the French AML Intergroup. Blood 2003;102(2):462 -9.
14. Poirel H, Radford -Weiss I, Rack K, et al. Detection of the chromosome 16 CBF beta -MYH11 fusion transcript in myelomonocytic leukemias. Blood 1995;85(5):1313 -22.
15. Martin G, Barragan E, Bolufer P, et al. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement. Haematologica 2000;85(7):699 -703.
16. Kömür M, Erbey F, Bayram İ, Yanyeli A. Incidence and p rognostic i mportance of m olecular g enetic defects in children with acute myeloblastic leukemia . Asian Pac J Cancer Prev 2010;11(5):1393 -5 .